Fed Regist. 2017 Sep 29;82(188):45511-4.
The Health Resources and Services Administration (HRSA) administers section 340B of the Public Health Service Act (PHSA), known as the "340B Drug Pricing Program" or the "340B Program." HRSA published a final rule on January 5, 2017, that set forth the calculation of the ceiling price and application of civil monetary penalties. The final rule applied to all drug manufacturers that are required to make their drugs available to covered entities under the 340B Program. On August 21, 2017, HHS solicited comments on further delaying the effective date of the January 5, 2017, final rule to July 1, 2018 (82 FR 39553). HHS proposed this action to allow a more deliberate process of considering alternative and supplemental regulatory provisions and to allow for sufficient time for additional rulemaking. After consideration of the comments received on the proposed rule, HHS is delaying the effective date of the January 5, 2017, final rule, to July 1, 2018.
卫生资源与服务管理局(HRSA)负责管理《公共卫生服务法》(PHSA)第340B条,即所谓的“340B药品定价计划”或“340B计划”。HRSA于2017年1月5日发布了一项最终规则,规定了最高限价的计算方法和民事罚款的适用情况。该最终规则适用于所有根据340B计划要求向覆盖实体提供药品的药品制造商。2017年8月21日,美国卫生与公众服务部(HHS)就进一步将2017年1月5日最终规则的生效日期推迟至2018年7月1日征求意见(82联邦法规39553)。HHS提出这一行动是为了让考虑替代和补充监管规定的过程更加审慎,并为额外的规则制定留出足够时间。在考虑了对拟议规则收到的意见后,HHS将2017年1月5日最终规则的生效日期推迟至2018年7月1日。